Indication
Moraxella catarrhalis bronchitis
*Moraxella catarrhalis* bronchitis is a lower respiratory tract infection characterized by acute inflammation of the bronchial mucosa caused by the Gram-negative diplococcus *Moraxella catarrhalis*. Read more about Moraxella catarrhalis bronchitis
227 drugs 95 manufacturers
Drugs that treat it
Common Moraxella catarrhalis bronchitis therapies.
CIPROFLOXACIN HCL
CIPROFLOXACIN HCL
CIPROFLOXACIN HCL
CIPROFLOXACIN HCL
CEFDINIR
LEVOFLOXACIN
CEFPROZIL
CIPROFLOXACIN HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soon*Moraxella catarrhalis* bronchitis is a lower respiratory tract infection characterized by acute inflammation of the bronchial mucosa caused by the Gram-negative diplococcus *Moraxella catarrhalis*.
While acute tracheobronchitis can develop in immunocompromised hosts, this infection predominantly manifests as an acute bacterial exacerbation of chronic bronchitis in older adults and individuals with pre-existing chronic obstructive pulmonary disease (COPD) or compromised mucociliary clearance.
Pathophysiologically, colonization and mucosal invasion trigger neutrophil-mediated airway inflammation, clinically presenting with increased dyspnea, worsening cough, and a marked increase in sputum volume and purulence.
- nih.gov
*Moraxella catarrhalis* bronchitis is a lower respiratory tract infection characterized by acute inflammation of the bronchial mucosa caused by the Gram-negative diplococcus *Moraxella catarrhalis* While acute tracheobronchitis can develop in immunocompromised hosts, this infection predominantly manifests as an acute bacterial exacerbation of chronic bronchitis in older adults and individuals with pre-existing chronic obstructive pulmonary disease (COPD) or compromised mucociliary clearance
- merckmanuals.com
*Moraxella catarrhalis* bronchitis is a lower respiratory tract infection characterized by acute inflammation of the bronchial mucosa caused by the Gram-negative diplococcus *Moraxella catarrhalis* Pathophysiologically, colonization and mucosal invasion trigger neutrophil-mediated airway inflammation, clinically presenting with increased dyspnea, worsening cough, and a marked increase in sputum volume and purulence
- nih.gov
While acute tracheobronchitis can develop in immunocompromised hosts, this infection predominantly manifests as an acute bacterial exacerbation of chronic bronchitis in older adults and individuals with pre-existing chronic obstructive pulmonary disease (COPD) or compromised mucociliary clearance
- healthline.com
While acute tracheobronchitis can develop in immunocompromised hosts, this infection predominantly manifests as an acute bacterial exacerbation of chronic bronchitis in older adults and individuals with pre-existing chronic obstructive pulmonary disease (COPD) or compromised mucociliary clearance
- buffalo.edu
Pathophysiologically, colonization and mucosal invasion trigger neutrophil-mediated airway inflammation, clinically presenting with increased dyspnea, worsening cough, and a marked increase in sputum volume and purulence
- ajmc.com
Pathophysiologically, colonization and mucosal invasion trigger neutrophil-mediated airway inflammation, clinically presenting with increased dyspnea, worsening cough, and a marked increase in sputum volume and purulence
Personalize your experience
Follow Moraxella catarrhalis bronchitis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.